Clover Health Investments (CLOV) Cost of Revenue (2020 - 2026)

Clover Health Investments has reported Cost of Revenue for 7 years, with the latest figure at $589.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 66.83% year-over-year to $589.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.8 billion (up 64.86% YoY), and the FY2025 full-year result was $1.6 billion, up 55.85% from the prior year.
• Cost of Revenue for Q1 2026 stood at $589.6 million, up from $413.5 million in the prior quarter.
• The five-year high for Cost of Revenue was $861.7 million in Q1 2022, with the low at -$1.6 billion in Q4 2022.
• Historically, Cost of Revenue has averaged $303.6 million across 5 years, with a median of $274.8 million in 2023.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 301.89% — and 2023, when it plunged 71.92%.
• Clover Health Investments' Cost of Revenue stood at -$1.6 billion in 2022, then surged by 115.94% to $249.8 million in 2023, then retreated by 2.69% to $243.0 million in 2024, then surged by 70.13% to $413.5 million in 2025, then surged by 42.6% to $589.6 million in 2026.
• The last three Cost of Revenue figures came in at $589.6 million (Q1 2026), $413.5 million (Q4 2025), and $423.5 million (Q3 2025), per Business Quant data.